|
3 Companies |
|
2 Products |
|
2 Products |
|
3 Mechanisms of Action |
|
0 Trials |
|
10 News |
|
- Trial completion, Trial primary completion date: Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities (clinicaltrials.gov) - Jul 26, 2016
P=N/A, N=57, Completed, Sponsor: Nationwide Children's Hospital
Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Jul 2016
- | Brineura (cerliponase alfa) / BioMarin
Trial completion: A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease (clinicaltrials.gov) - Apr 27, 2016
P1/2, N=24, Completed, Sponsor: BioMarin Pharmaceutical
Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Jul 2016 Active, not recruiting --> Completed
- Trial termination: Collection of Cerebrospinal Fluid in Healthy Children (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=32, Terminated, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Completed Enrolling by invitation --> Terminated; Study interest shifted
- acetylcysteine solution / Generic mfg.
Phase classification, Combination therapy: Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis (clinicaltrials.gov) - Jan 22, 2015
P4, N=10, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Enrolling by invitation --> Terminated; Study interest shifted Phase classification: P2 --> P4
- | Brineura (cerliponase alfa) / BioMarin
Enrollment closed: A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease (clinicaltrials.gov) - Jan 6, 2015
P1/2, N=22, Active, not recruiting, Sponsor: BioMarin Pharmaceutical
Phase classification: P2 --> P4 Recruiting --> Active, not recruiting
- acetylcysteine solution / Generic mfg.
Trial completion, Combination therapy: Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis (clinicaltrials.gov) - Dec 12, 2013
P2, N=9, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Brineura (cerliponase alfa) / BioMarin
Enrollment open: A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease (clinicaltrials.gov) - Sep 10, 2013
P1/2, N=22, Recruiting, Sponsor: BioMarin Pharmaceutical
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Brineura (cerliponase alfa) / BioMarin
New P1/2 trial: A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease (clinicaltrials.gov) - Jul 22, 2013
P1/2, N=22, Recruiting, Sponsor: BioMarin Pharmaceutical
- Enrollment change: Genotype - Phenotype Correlations of LINCL (clinicaltrials.gov) - Jul 7, 2013
P=N/A, N=18, Completed, Sponsor: Weill Medical College of Cornell University
Not yet recruiting --> Recruiting N=30 --> 18
- HuCNS-SC / Microbot Medical
Trial withdrawal: Safety and Efficacy Study of HuCNS-SC in Subjects With Neuronal Ceroid Lipofuscinosis (clinicaltrials.gov) - May 23, 2012
P1, N=0, Withdrawn, Sponsor: StemCells, Inc.
N=30 --> 18 Terminated --> Withdrawn